January 04, 2012
Two pharmacies hit Pfizer Inc. unit King Pharmaceuticals Inc. with a proposed competition class action Wednesday in Tennessee, alleging that they paid inflated prices for the muscle relaxant Skelaxin because King reached an illegal agreement to keep generic versions off the market.